CD274 and pneumonitis: The pooled subgroup analysis indicates a higher incidence of grade ≥3 pneumonitis in patients treated with PD-1 inhibitors, i.e., pembrolizumab and nivolumab: event rate of 2.4% (95% CI [1.9%, 3.1%]) and 1.3% (95% CI [0.8%, 2.0%]), respectively, than PD-L1 inhibitor, atezolizumab: event rate of 0.7% (95% CI [0.3%, 1.6%]) (Figure 5).